绿叶制药(02186.HK)拟8月28日举行董事会会议以审批中期业绩

Core Viewpoint - The company, Green Leaf Pharmaceutical (02186.HK), is set to hold a board meeting on August 28, 2025, to approve its mid-term performance for the six months ending June 30, 2025, and to consider the distribution of an interim dividend, if applicable [1] Related Events - Green Leaf Pharmaceutical plans to hold a board meeting on August 28 to approve mid-term performance [1] - The company has completed patient enrollment for the Phase III clinical trial of Ruxolitinib for the treatment of generalized anxiety disorder in China [1]